Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin in Opioid Use Disorder
NCT06160284Phase 1Recruiting
- Sponsor
- Yale University
- Start
- May 2025
- Primary completion
- Jan 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of psilocybin in opioid use disorder (OUD), sponsored by Yale University. Primary endpoints: Change in Synaptic Density, Association between VT and BPND up to 12 weeks and 2 more. Started May 2025; status: recruiting.
02
Drugs
psilocybin
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT06160284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06160284.